Analysts Anticipate PDS Biotechnology Co. (NASDAQ:PDSB) to Post -$0.30 Earnings Per Share

Wall Street brokerages expect PDS Biotechnology Co. (NASDAQ:PDSBGet Rating) to post earnings per share of ($0.30) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for PDS Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.33). PDS Biotechnology reported earnings of ($0.22) per share in the same quarter last year, which would indicate a negative year over year growth rate of 36.4%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that PDS Biotechnology will report full year earnings of ($1.16) per share for the current financial year, with EPS estimates ranging from ($1.38) to ($0.89). For the next financial year, analysts anticipate that the company will post earnings of ($0.52) per share, with EPS estimates ranging from ($1.12) to $0.09. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for PDS Biotechnology.

PDS Biotechnology (NASDAQ:PDSBGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). During the same period in the previous year, the company posted ($0.14) EPS.

Several research analysts recently issued reports on PDSB shares. Alliance Global Partners dropped their price objective on PDS Biotechnology from $18.00 to $16.00 in a research note on Friday. Noble Financial restated a “buy” rating and set a $22.00 price target on shares of PDS Biotechnology in a research note on Thursday, May 12th. raised shares of PDS Biotechnology to a “sell” rating in a research note on Saturday, April 9th. Finally, Zacks Investment Research lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, PDS Biotechnology currently has an average rating of “Buy” and a consensus price target of $19.00.

Shares of NASDAQ:PDSB traded up $0.08 during trading on Tuesday, reaching $5.23. 4,205 shares of the company were exchanged, compared to its average volume of 286,967. The business’s fifty day simple moving average is $5.66 and its 200-day simple moving average is $7.15. PDS Biotechnology has a 12-month low of $3.47 and a 12-month high of $17.85. The firm has a market capitalization of $148.79 million, a PE ratio of -6.38 and a beta of 2.33.

Institutional investors have recently modified their holdings of the business. Amussen Hunsaker Associates LLC raised its stake in shares of PDS Biotechnology by 5.9% during the 3rd quarter. Amussen Hunsaker Associates LLC now owns 26,739 shares of the company’s stock valued at $398,000 after buying an additional 1,500 shares during the last quarter. BlackRock Inc. increased its holdings in PDS Biotechnology by 0.5% in the fourth quarter. BlackRock Inc. now owns 431,405 shares of the company’s stock valued at $3,495,000 after buying an additional 2,227 shares in the last quarter. Northern Trust Corp increased its stake in shares of PDS Biotechnology by 6.3% in the 4th quarter. Northern Trust Corp now owns 41,820 shares of the company’s stock valued at $339,000 after purchasing an additional 2,466 shares in the last quarter. UBS Group AG acquired a new position in PDS Biotechnology in the 3rd quarter worth about $44,000. Finally, State Street Corp boosted its position in PDS Biotechnology by 5.6% during the first quarter. State Street Corp now owns 76,533 shares of the company’s stock worth $474,000 after purchasing an additional 4,057 shares in the last quarter. Institutional investors and hedge funds own 20.94% of the company’s stock.

PDS Biotechnology Company Profile (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Featured Stories

Get a free copy of the Zacks research report on PDS Biotechnology (PDSB)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with's FREE daily email newsletter.